Davis Capital Management
HRMY icon

Davis Capital Management’s Harmony Biosciences HRMY Stock Holding History

Davis Capital Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$79 Hold
2
– – ﹤0.01% 1072
2026
Q2 		$73 Buy
+2
New +$63 ﹤0.01% 1139

Other funds holding HRMY

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
Royce & Associates
Royce & Associates New York $11B AUM 39.4% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $668M AUM 8.93% 1-Year Est. Return
Bridge City Capital
Bridge City Capital Lake Oswego, Oregon $480M AUM 47.16% 1-Year Est. Return

Davis Capital Management's HRMY Position: Q3 2026 in Review

Davis Capital Management held its Harmony Biosciences (HRMY) position steady in Q3 2026 at 2 shares worth $79. The position accounts for ﹤0.01% of the portfolio, ranked #1072.

Davis Capital Management first reported a position in HRMY in Q2 2026 and has held it in 2 quarters since. 156 funds tracked by Wall St. Rank hold HRMY as of Q3 2026.

  • Davis Capital Management held 2 shares of Harmony Biosciences worth $79 as of Q3 2026.
  • Davis Capital Management left its Harmony Biosciences share count unchanged in Q3 2026.
  • Harmony Biosciences made up ﹤0.01% of Davis Capital Management's portfolio in Q3 2026, its #1072 holding.
  • Davis Capital Management first reported a position in Harmony Biosciences in Q2 2026 and has held it in 2 quarters since.
  • 156 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2026.

Based on Davis Capital Management's 13F filing for Q3 2026, filed 8 Oct 2026.